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      Chronic myeloid leukemia (CML) is a myeloproliferative disease of the hematopoietic stem cells, 
characterized by the presence of the Philadelphia (Ph) chromosome. Although imatinib inhibits the BCR-
ABL kinase activity, clinical experiences confirm that imatinib may not target CML stem cells in vivo. The 
identification of signaling pathways responsible for the self-renewal properties of leukemic stem cells in 
CML will help in the discovery of novel therapeutic targets. Here we review signaling pathways including 
Wnt/β-catenin, Hedgehog, Alox5, and Foxo which play crucial roles in the maintenance of stem cell 
functions in CML. It is thought that inhibition of key genes that are part of self-renewal associated signaling 
pathways may provide an effective way to reduce aberrant stem cell renewal in CML. 
 




     Cancer stem cells are a small subpopulation of 
malignant cells identified in a variety of tumors 
(or leukemias) that are defined by their ability to 
undergo self-renewal, as well as multi-lineage 
differentiation, resulting in therapeutic resistance 
and cancer progression. Self-renewal is 
discriminated from other proliferating processes 
since at least one of progeny is identical to the 
primary stem cell. Dysregulation of stem cell self-
renewal is a likely requisite for the initiation, 
progression, and therapeutic resistance of cancer 
[1-5]. The cancer stem cell hypothesis postulates 
that cancers are derived from a self-renewing 
cancer stem cell population that is also capable of 
initiating/maintaining cancer. Thus, according to 
the cancer stem cell hypothesis, these cells with 
the unique self-renewal ability are tumor-
initiating cells that differentiate into non-self-
renewing cells that comprise the bulk of the tumor 
[6-9]. Cancer stem cells were initially identified in 
leukemia [10,11] but has since expanded to solid 
tumors such as brain, breast, pancreas, colon, and 
head and neck cancer [3,12-22]. 
     Chronic myeloid leukemia (CML) is a 
monoclonal myeloproliferative disorder of the 
hematopoietic stem cells, characterized by the 
presence of the Philadelphia (Ph) chromosome 
genetic abnormality which arises from the 
reciprocal translocation t(9; 22) (q34; q11). This 
translocation leads to the fusion of the Breakpoint 
Cluster Region (BCR) gene to the Abelson 
Tyrosine Kinase (ABL1) proto-oncogene and the 
formation of the BCR-ABL oncogene [23,24]. 
Depending on the precise translocation 
breakpoints and differential mRNA splicing, 
various molecular weight isoforms of BCR-ABL 
(P190, P210, and P230 isoforms) are generated. 
The BCR-ABL oncogenes produce a 
constitutively active non-receptor tyrosine kinase 
which deregulates several signal transduction 
pathways that ultimately lead to abnormal cell 
cycling, increased proliferation, and inhibition of 
apoptosis [24-26]. 
 





      The natural course of the disease is usually 
characterized by three sequential stages (The 
chronic, accelerated, and blast-crisis). Initially, 
CML is a slowly progressive disease with 
symptoms that usually develop gradually [27]. As 
the disease progresses, the number of blasts in the 
bone marrow and peripheral blood is increased, 
and accelerated phase of the disease will evolve to 
an aggressive acute leukemia, referred to as a 
blast crisis [28], during which progressive 
resistance to therapy is acquired [29,30]. The 
transition from chronic to the accelerated and 
blast phases is presumed to occur due to 
secondary genetic changes [31]. 
 
CML STEM CELLS ARE RESISTANT 
TO BCR-ABL KINASE INHIBITOR 
IMATINIB 
      The development of the BCR-ABL kinase 
inhibitor imatinib was a breakthrough in the 
therapy of chronic-phase CML, establishing 
imatinib as the first-line therapy for newly 
diagnosed CML. A 5 year follow-up of patients 
receiving imatinib as initial therapy demonstrated 
complete hematological response in 98% of the 
treated patients, a complete cytogenetic response 
in 87%, and a complete molecular response in 
about 35%. The study showed a relapse rate of 
17% during continuous treatment and 7% of 
patients progressed to the accelerated phase or 
blast crisis. However, 4% of patients discontinued 
therapy owing to an adverse event [32].  
      Although continuous treatment of chronic-
phase CML with imatinib was found to induce 
durable responses, several reports indicate that 
discontinuation of imatinib therapy even after 
achieving a molecular remission induces a relapse 
of the disease [33-37], and therefore, patients are 
forced to undergo lifelong therapy [33,38-40]. 
Further studies have been shown that BCR-ABL-
positive leukemic stem cells are relatively 
resistant to therapies that target rapidly dividing 
cells, and thus contribute to avoid apoptosis, 
renew themselves, and survive long term [41-43]. 
This is supported because BCR-ABL-positive 
leukemic stem cells remain present in the 
patient’s bone marrow even after long-term 
treatment with imatinib and can cause relapse of 
the disease [44,45]. These findings propose that 
inhibition of BCR-ABL tyrosine kinase activity 
alone is insufficient to eradicate leukemic stem 
cells and cannot cure CML. Therefore, 
development of efficient therapeutic strategies 
capable of eradicating CML stem cells would 
provide noticeably improved therapeutic benefits 



















Figure 1. CML stem cells are resistant to BCR-ABL kinase inhibitor imatinib. A. Although tyrosine kinase inhibitor imatinib 
inhibits the BCR-ABL kinase activity and decreases the number of CML cells, it does not target CML stem cells. This leads to 
 





relapse of the disease. B. By targeting key genes that are part of the self-renewal associated signaling pathways, it could be possible 
to reduce aberrant stem cell renewal in CML. Residual cells are not able to support cancer and undergo apoptosis or differentiation. 
This strategy may prevent drug resistance and disease recurrence associated with imatinib treatment of CML.  
 
CRITICAL SELF-RENEWAL 
ASSOCIATED SIGNALING PATHWAYS 
IN CML STEM CELLS 
      Since both normal hematopoietic stem cells 
and CML stem cells are capable of self-renewing, 
it is not surprising that several signaling pathways 
which are involved in the regulation of normal 
stem cells may play significant roles in cancer 
stem cell biology. It has been shown that BCR-
ABL promotes self-renewal of leukemic stem 
cells because all critical signaling pathways 
involved in the maintenance of survival of 
leukemic stem cells can be activated by BCR-
ABL [51]. However, BCR-ABL oncogene cannot 
confer self-renewal capacity to committed 
progenitors to transform them and therefore rather 
utilizes and enhances the self-renewal properties 
inherent in existing self-renewing cells (i.e., 
hematopoietic stem cells) [52,53]. Here we review 
molecular pathways involved in the regulation of 
self-renewal properties in leukemic stem cells, 
and discuss their implication in regulating 
leukemic stem cell functions in CML. These self-
renewal associated signaling pathways include 





      The Wnt/β-catenin signaling pathway is 
involved in self-renewal of both normal 
hematopoietic stem cells and CML stem cells [54-
57]. In blast crisis CML patients, β-catenin is 
activated in myeloid progenitors and the leukemic 
stem cells, which resemble granulocyte 
macrophage-progenitors (GMPs) have aberrant 
activation of β-catenin via canonical Wnt 
signaling pathway [58].  
      Using a β-catenin-deficient mice model of 
CML, Zhao et al [59] demonstrated dependence 
of in vivo myeloid leukemia progression on β-
catenin. They were able to show that loss of β-
catenin impairs self-renewal of CML stem cells in 
vivo and subsequently reduces in vivo progression 
of CML, whereas it allows normal development 
of acute lymphoblastic leukemia (ALL). As CML 
is thought to be initiated in hematopoietic stem 
cells and ALL may be initiated in committed 
progenitors, these findings proposed that β-
catenin is required for BCR-ABL-induced 
leukemias that originate in stem cells. Another 
study led by Hu et al [60] showed that β-catenin is 
essential for the maintenance of leukemic stem 
cells resistant to tyrosine kinase inhibition in mice 
model of CML. Delayed development of CML 
due to loss of β-catenin is attributed to a reduced 
ability of BCR-ABL to support long-term self-
renewal property of leukemic stem cells. Overall, 
these findings suggest that Wnt signaling could be 
considered as a promising therapeutic target for 
curing CML. 
 
HEDGEHOG SIGNALING PATHWAY 
      Hedgehog (Hh) signaling is a highly 
conserved developmental pathway which 
regulates self-renewal of normal hematopoietic 
stem cells and CML stem cells [61-64]. Hh 
signaling is triggered by the binding of the Hh 
protein ligands (Sonic hedgehog [Shh], Indian 
hedgehog [Ihh], and Desert Hh [Dhh]) to the 12 
transmembrane receptor patched (PTCH), which 
is a negative regulator of the seven 
transmembrane receptor smoothened (Smo). 
Upon ligand binding, the inhibitory effect on Smo 
is relived. This signaling event leads to the 
induction of Gli transcription factors, which 
promotes transcription of Hh-responsive genes 
such as Gli1, Ptch1, cyclin D1, and Bcl-2 [65-69]. 
      Hh signaling has been proven as a functional 
pathway for leukemic stem cells, and loss of this 
pathway impairs CML progression [38,70,71]. 
Dierks et al [38] indicated that Smo, which is 
specifically upregulated in BCR-ABL-positive 
cells, is essential for the expansion of the 
leukemic stem cell pool. While lack of Smo had 
no effect on long-term reconstitution of normal 
hematopoiesis, the absence of Smo expression 
 





effectively reduced the development of BCR-
ABL-positive leukemias in mice. Moreover, 
pharmacological inhibition of Hh signaling had no 
effect on regular hematopoiesis but reduced 
leukemic stem cells in vivo and enhanced time to 
relapse of the disease. Supporting the previous 
study, Zhao et al [71] have shown that the loss of 
Smo impaired hematopoietic stem cell renewal 
and decreased induction of CML by the BCR-
ABL oncoprotein. Loss of Smo caused depletion 
of CML stem cells, whereas overexpression of 
Smo led to an increased percentage of CML stem 
cells and accelerates the progression of disease. 
As a possible mechanism, the inhibitory effects of 
the Smo deletion on leukemic stem cells might be 
attributed to the regulation of the cell fate 
determinant Numb, because the Smo deletion 
leads to an increase in the expression levels of 
Numb, which depletes CML stem cells. Taken 
together, these findings suggest that Hh inhibition 
might be a promising therapeutic strategy to 
reduce the leukemic stem cell pool in drug 
resistant CML. 
 
ALOX5 SIGNALING PATHWAY 
      The arachidonate 5-lipoxygenase (5-LO) gene 
(Alox5) has been shown to be involved in several 
physiological and pathological process including 
oxidative stress response, inflammation, and 
cancer [72-74]. Alox5 function has been 
implicated in several critical signaling pathways 
such as p53 [72], NF-kB [75], and PI3k [75]. It 
has been also found that Alox5 is a critical 
regulator for leukemic stem cells and its function 
is essential for the induction of CML by BCR-
ABL.  
      Transcriptional analysis-based studies have 
shown that Alox5 is differentially expressed in 
human CD34+ CML cells compared to their 
normal counterparts, proposing a possible role of 
Alox5 in CML stem cells [76]. A microarray 
analysis of gene expression in leukemic stem cells 
in mice model of CML indicated that the Alox5 
gene was upregulated by BCR-ABL and this 
upregulation was not abolished by BCR-ABL 
kinase inhibitors [77]. This at least partially 
explains why imatinib had no effect on leukemic 
stem cells in mice model of CML [45]. It has been 
shown that the Alox5 deficiency impaired the 
function of leukemic stem cells through affecting 
differentiation, cell division, and survival of 
leukemic stem cells, consequently causing a 
gradual depletion of leukemic stem cells. This 
explains why BCR-ABL failed to induce CML in 
mice in the absence of Alox5 [72,74,77-79]. 
Importantly, the lack of Aox5 had no significant 
effect on the function of normal hematopoietic 
stem cells, suggesting a possible mechanism for 
how hematopoietic stem cells and leukemic stem 
cells distinctly self-renew and differentiate 
[77,80]. Altogether, these findings proposed that 
Alox5 could be a specific target gene in CML 
stem cells for developing curative therapies. 
 
FOXO SIGNALING PATHWAY 
      Forkhead box class O (Foxo) transcription 
factors are involved in the maintenance of normal 
hematopoietic stem cells and CML stem cells. 
There are four members (Foxo1, Foxo3a, Foxo4, 
and Foxo6), all of which are functional 
downstream targets of phosphatidylinositol 3 
kinase (PI3K)-AKT pathway [81-83]. In the 
absence of stimulation by growth factors or 
insulin, Foxos localize to the nucleus and activate 
their transcriptional targets regulating oxidative 
stress responses, cell cycle progression, and 
apoptosis [84-86]. Upon growth factor or insulin 
binds to the cell surface receptor, AKT is 
activated and directly phosphorylates Foxo 
members, leading to the exclusion of Foxo 
members from the nucleus and suppression of 
Foxo transcriptional activity. In the cytoplasm, 
Foxo members are degraded [87-89]. 
      Tothova et al [82] demonstrated that Foxos 
are critical mediators of hematopoietic stem cell 
resistance to physiologic oxidative stress and that 
triple conditional deletion of Foxo1, Foxo3a, and 
Foxo4 in mice leads to a significant increase in 
the hematopoietic stem cell population. Several 
studies showed that Foxo3a alone is essential to 
maintenance the self-renewal capacity of normal 
hematopoietic stem cells and CML stem cells 
[83,90,91]. High levels of Akt phosphorylation 
and cytoplasmic localization of Foxo3a have been 
found in non-CML stem cells. In contrast, cells 
with low levels of Akt phosphorylation and 
 





nuclear localization of Foxo3a were enriched in 
the CML stem cell population [90]. Foxo3a 
deficient mice showed a reduction of leukemic 
stem cells after serial transplantation in BCR-
ABL driven CML mouse model. This was 
associated with decreased ability of leukemic 
stem cells to promote disease in vivo. These 
results suggest that Foxo3a is essential for long-
term maintenance of leukemia-initiating potential 
in CML stem cells [90] and that targeting Foxo 
transcription factors might be a potential 
therapeutic approach to eradicate leukemic stem 
cells in CML. 
  
THE NECESSITY OF TARGETING 
MOLECULAR PATHWAYS IN CML 
STEM CELLS 
      Since both hematopoietic stem cells and CML 
stem cells may share many survival signaling 
pathways, elucidation of the hematopoietic 
developmental stage of survival gene expression 
will be important for developing therapies which 
specifically target cancer stem cells while sparing 
normal stem cells. Moreover, by targeting key 
genes that are part of the self-renewal associated 
signaling pathways, it could be possible to reduce 
aberrant stem cell renewal in CML. This strategy 
may prevent drug resistance and disease 
recurrence associated with imatinib treatment of 
CML [45,92-96].  
 
MICRORNA 
      MicroRNAs (miRNAs or miRs) are a novel 
class of small non-coding regulatory RNAs which 
control gene expression at the post-transcriptional 
levels. The official miRNA database miRBase 
lists that up to 30% of human genome is 
controlled by miRNAs. There is currently 
intensive research aimed at identifying all 
miRNAs, their target mRNAs and their biological 
functions [97-99]. MiRNAs have been shown to 
become involved in a variety of biological 
processes such as cellular proliferation, 
differentiation, apoptosis, and maintenance of 
stem cell potency [97,100-103]. Certain miRNAs 
have been shown to be aberrantly expressed 
human cancers and a large body of evidence 
points to their critical roles as oncogenes and 
tumor suppressors in the development of various 
human malignancies including leukemias [104-
108]. Moreover, it seems that aberrant expression 
of certain miRNAs results in dysregulation of 
stem cell genes which, in turn, causes an increase 
in self-renewal potential of cancer stem cells 
[109,110]. Understanding the biological functions 
of miRNAs will require the identification of their 
multiple targets and the pathways that they 
control. 
 
BIOGENESIS, PROCESSING AND 
FUNCTION OF MICRORNAS 
      MiRNAs are first transcribed by RNA 
polymerase II or III as primary miRNAs (pri-
miRNAs), which are RNA hairpin structures up to 
several thousand nucleotides in length. In the 
nucleus, pri-miRNAs are processed by the 
“microprocessor complex” which consists of 
RNase III endonuclease Drosha bound to 
accessory protein DiGeorge syndrome critical 
region 8 (DGCR8). This converts pri-miRNAs to 
intermediate stem-loop structures approximately 
70 nucleotides long called “precursor miRNAs” 
(pre-miRNAs) [111,112]. Following nuclear 
processing, pre-miRNAs are exported to the 
cytoplasm by exportin-5 in a GTP-dependent 
manner. The pre-miRNAs are subsequently 
processed by the cytoplasmic RNase III 
endonuclease Dicer, releasing double-stranded 
mature miRNAs. The strand which becomes the 
mature miRNA is the one whose 5’ end is more 
unstable, thus more easily unwind by the helicase. 
Another strand is released and subsequently 
degraded in the cytoplasm. Mature miRNA is 
incorporated into the RNA-induced silencing 
complex (RISC), the effector of RNA interference 
(RNAi) pathway [99,100,113].  
      The RISC-miRNA complex typically 
recognizes and targets the 3’-untranslated region 
(3’-UTR) of specific mRNAs bearing a perfectly 
complementary target site for degradation or can 
repress the translation of an mRNA that contains 
several partly mismatched target sites [114]. 
Recently, however, evidence indicates that 
miRNAs can also regulate gene expression 
through binding “seedless” 3’-UTR miRNA 
recognition elements [115] or by binding to sites 
 









MICRORNA INVOLVEMENT IN CML 
      MicroRNA involvement in CML presents an 
additional layer of complexity to understanding 
the development and progression of the disease. 
The involvement of miRNAs in the regulation of 
several cellular processes altered in CML, such as 
cell cycle, apoptosis, and adhesion [107], 
establishes these small RNA molecules as 
potential players in pathogenesis of CML. 
Functional analysis of individual miRNA is 
necessary to understand altered cellular process. 
The first evidence for the involvement of 
miRNAs in hematologic malignancies was 
described in chronic lymphocytic leukemia (CLL) 
[117]. Subsequent miRNA expression profiling 
studies based on sequencing [118,119], 
microarray [117,120], and quantitative real-time 
PCR [120-122] revealed miRNA signatures 
characterizing ALL, acute promyelocytic 
leukemia (APL), and acute myeloid leukemia 
(AML) associated with various cytogenetic 
abnormalities [123-125]. Information about the 
involvement of miRNAs in CML pathogenesis is 
restricted to the description of downregulation of 
certain miRNAs (miR-15a, miR-16-1, miR-155, 
miR-181, miR-221, and let-7a) in the CML cell 
line k562 [104,126,127] and upregulation of miR-
17-92 in CML patients [128]. 
      Venturini et al [128] were able to show that 
expression of the polycistronic miR-17-92 cluster 
which is transcriptionally regulated by c-MYC, 
are increased in CML CD34+ cells from patients 
in chronic phase but not in blast crisis compared 
with normal CD34+ cells, suggesting  a BCR-
ABL-c-MYC-miR-17-92 pathway in CML cells. 
Agirre et al [126] identified an abnormal miRNA 
expression profile in mononuclear and CD34+ 
cells from patients with CML compared with 
healthy controls. Expression analysis of 157 
miRNAs in patients with newly diagnosed CML 
revealed that miR-10a, miR-150, and miR-151 
were downregulated, whereas miR-96 was 
upregulated in CML cells. Interestingly, this study 
showed that downregulation of miR-10a was not 
dependent on BCR-ABL activity and resulted in 
the increased upstream stimulator factor 2 
transcription factor (USF2)-mediated cell growth 
of CML cells, supporting the potential role of a 
miRNA in the abnormal behavior of CML.  
      MiR-15a and miR-16-1, two p53-induced 
miRNAs with tumor suppressive activity, 
negatively regulate expression of the anti-
apoptotic proto-oncogene Bcl-2 at the 
posttranscriptional level, inducing apoptosis in 
leukemic cells [129]. It has been shown that Bcl-2 
overexpression results in the prevention of 
apoptosis which, in turn, leads to an increase in 
number and repopulation potential of stem cells in 
vivo [130,131]. Therefore, it seems that apoptosis 
has a possible role in regulating the 
microenvironments of stem cells. This highlights 
the importance of the Bcl-2 signaling pathway for 
the survival of stem cells and suggests a possible 
role for miR-15a/16-1 in regulating apoptosis in 
stem cells. 
      It seems that miRNA antagonists, referred as 
“antagomiRs”, can block the oncogenic properties 
of the miRNAs and miRNA mimics can restore 
the expression levels of miRNAs with tumor 
suppressive activity [132-138]. Therefore, 
miRNAs could be considered as promising 
therapeutic targets in addressing cancer stem cell 
dysregulation. 
 
CONCLUSION AND FUTURE 
PERSPECTIVES 
The identification of key genes that are part of 
self-renewal signaling pathways in CML stem 
cells provides new opportunities in the future of 
leukemia therapy. As aberrant expressions of 
miRNAs are associated with cancer stem cell 
dysregulation, it seems that miRNA-based 
molecular leukemia therapy eliminates the self-
renewal capabilities of CML stem cells. 
Obviously, further investigations are needed to 
gain more insights into the therapeutic potential of 
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